Neurimmune acquires USD 1.9m funding from Swiss CTI

01.01.2012

Neurimmune acquires USD 1.9m funding from Swiss CTI for its innovative program in type-2 diabetes an d for starting a new project by applying its proprietary RTM technology in infectious disease. Both publicly funded collaborative projects are accompanied by collaboration agreements ensuring Neurimmune’s full and exclusive access to related IP rights.

News overview

This website uses cookies, with the aim of ensuring that you have the best possible online experience. In using our website, you are giving your consent to the terms and conditions of our Privacy policy

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue